Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) today announced that the independent Data Safety Monitoring Board (DSMB) of SEAMLESS, recommended that the Phase 3, randomized, registration-directed study of sapacitabine in elderly patients with acute myeloid leukemia (AML) should enter the randomized stage as planned. Judy H. Chiao , M.D., Vice President, Clinical Development and Regulatory Affairs of […]